Abstract
Background
Many recent studies focus on the immunohistochemical evaluation of Bcl-2 expression, and its prognostic significance in colorectal cancer (CRC). Our aim was to investigate the presence of bcl-2 protein in the serum and to examine the association between its levels, stage and tumour load, in patients with CRC.
Methods
A commercially available ELISA was used for the estimation of bcl-2 levels, in 94 patients with different stages of CRC. Forty-eight healthy blood donors served as controls. Concentrations ranging 2SD above and below the controls median were accepted as “normal”.
Results
bcl-2 was detected in the serum of patients with CRC. A significantly higher proportion of patients with non-metastatic disease (61%), had high serum bcl-2 values, compared to patients with metastatic disease (28%, p<0.0001).
Conclusions
Serum bcl-2 in patients with CRC may reflect the degree of Bcl-2 expression in cancer tissue. Serum bcl-2 is easily determinable, and could be useful as a prognostic marker in CRC.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giannoulis, K., Fountzilas, G., Angouridakis, N. et al. Serum levels of bcl-2 in patients with colorectal cancer. Tech Coloproctol 8 (Suppl 1), s56–s58 (2004). https://doi.org/10.1007/s10151-004-0112-2
Issue Date:
DOI: https://doi.org/10.1007/s10151-004-0112-2